The role of complement in pregnancy and fetal loss

被引:40
作者
Girardi, G [1 ]
Salmon, JE [1 ]
机构
[1] Cornell Univ, Weill Med Coll, Hosp Special Surg, Dept Med, New York, NY 10021 USA
关键词
complement; inflammation; antiphospholipid antibodies; complement regulatory proteins;
D O I
10.1080/0891693031000067322
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In the United States, between 1 and 3% of women suffer recurrent miscarriages; 50-70% of all conceptions fail.([1,2]) Although in the majority of affected women the cause of recurrent miscarriages is unknown, an immune mechanism involving the inappropriate and subsequently injurious recognition of the conceptus by the mother's immune system has been proposed. Murine models have recently been developed that are relevant to this issue. We and others have identified a novel role for complement as an early effector in the pathway leading to pregnancy loss associated with placental inflammation. Indeed, it appears that inhibition of complement activation is an absolute requirement for normal pregnancy, and that in the antiphosphospholid syndrome overwhelming activation of complement triggered by antibodies (Ab) deposited in placenta leads to fetal injury. Identification of complement activation as a mediator of pregnancy loss and definition of the complement components necessary to trigger such injury is likely to lead to a better understanding of its pathogenesis and to new and improved treatments.
引用
收藏
页码:19 / 26
页数:8
相关论文
共 70 条
[1]  
Abbas AK, 2000, CELLULAR MOL IMMUNOL, P316
[2]   ACTIVATION OF THE COMPLEMENT PATHWAY - COMPARISON OF NORMAL-PREGNANCY, PREECLAMPSIA, AND SYSTEMIC LUPUS-ERYTHEMATOSUS DURING PREGNANCY [J].
ABRAMSON, SB ;
BUYON, JP .
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 1992, 28 (3-4) :183-187
[3]   Antiphospholipid (Hughes) syndrome in systemic lupus erythematosus [J].
Amigo, MC ;
Khamashta, MA .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2000, 26 (02) :331-+
[4]   TERMINAL COMPLEMENT PROTEINS C5B-9 RELEASE BASIC FIBROBLAST GROWTH-FACTOR AND PLATELET-DERIVED GROWTH-FACTOR FROM ENDOTHELIAL-CELLS [J].
BENZAQUEN, LR ;
NICHOLSONWELLER, A ;
HALPERIN, JA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (03) :985-992
[5]   COMPLEMENT RECEPTORS AND PHAGOCYTOSIS [J].
BROWN, EJ .
CURRENT OPINION IN IMMUNOLOGY, 1991, 3 (01) :76-82
[6]   The role of complement and complement receptors in induction and regulation of immunity [J].
Carroll, MC .
ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 :545-568
[7]  
CHAOUAT G, 1990, J REPROD FERTIL, V89, P447
[8]   AN INFORMATIVE PROTOCOL FOR THE INVESTIGATION OF RECURRENT MISCARRIAGE - PRELIMINARY EXPERIENCE OF 500 CONSECUTIVE CASES [J].
CLIFFORD, K ;
RAI, R ;
WATSON, H ;
REGAN, L .
HUMAN REPRODUCTION, 1994, 9 (07) :1328-1332
[9]   Upregulation of DAF (CD55) on orbital fibroblasts by cytokines.: Differential effects of TNF-β and TNF-α [J].
Cocuzzi, ET ;
Bardenstein, DS ;
Stavitsky, A ;
Sundarraj, N ;
Medof, ME .
CURRENT EYE RESEARCH, 2001, 23 (02) :86-92
[10]   DECAY-ACCELERATING FACTOR PROTECTS HUMAN TROPHOBLAST FROM COMPLEMENT-MEDIATED ATTACK [J].
CUNNINGHAM, DS ;
TICHENOR, JR .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1995, 74 (02) :156-161